RAF1 and non-small cell lung carcinoma: Several next-generation αC-helix IN RAF inhibitors, equipotent and dimer selective, including BGB-3245, BDTX-4933, exarafenib, and FORE8394, are currently under clinical evaluation as monotherapies for solid tumors bearing MAPK pathway mutations, including mutated NSCLC (Table 1, Figure 2) [75,76,77,78].